期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 24, 期 1, 页码 27-31出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2017.10.017
关键词
Chimeric antigen receptor T cells; CART; Immunotherapy; Adoptive T cell therapy; Adoptive immunotherapy; Hematopoietic stem cell transplantation; Cytokine release syndrome; Neurologic Toxicity
资金
- National Institutes of Health/National Cancer Institute Cancer Center Support Grant [P30 CA008748]
- NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER
Therapeutic T cell engineering has recently garnered widespread interest because of the success of CD19 chimeric antigen receptor (CAR) therapy. CARs are synthetic receptors for antigen that redirect the specificity and reprogram the function of the T cells in which they are genetically introduced. CARs targeting CD19, a cell surface molecule found in most leukemias and lymphomas, have yielded high remission rates in patients with chemorefractory, relapsed disease, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma. The toxicities of this treatment include B cell aplasia, cytokine release syndrome (CRS), and neurotoxicity. Although reversible in most instances, these toxicities may require specific medical interventions, including transfer to intensive care to treat severe CRS. Guidelines for managing these toxicities are emerging. The recent report of a nonhuman primate model for CRS is poised to help advance the management of this syndrome. Finally, new engineering modalities, based on the use of targeted nucleases like CRISPR, may further enhance the efficacy and safety of CAR T cells. (C) 2017 American Society for Blood and Marrow Transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据